Robert Striker (Rob Striker)

Publication Activity (10 Years)

Years Active: 2018-2022
Publications (10 Years): 5

Top Topics

Molecular Dynamics Simulations

Staphylococcus Aureus

Tyrosine Kinase

Mycobacterium Tuberculosis

Top Venues

International journal of colorectal disease

ACS infectious diseases

Molecular pharmaceutics

This page only lists publications with an associated author ORCID identifier.

Publications

Jonathan Stem, Qiuyu Yang, Evie H Carchman, Robert Striker, Cristina B Geltzeiler
Do immune inflammatory markers correlate with anal dysplasia and anal cancer risk in patients living with HIV? International journal of colorectal disease 37 (5) (2022)
Nathan Wlodarchak, John B Feltenberger, Zhengqing Ye, Jeffrey Beczkiewicz, Rebecca Procknow, Gang Yan, Troy M King, Jennifer E Golden, Robert Striker
Engineering Selectivity for Reduced Toxicity of Bacterial Kinase Inhibitors Using Structure-Guided Medicinal Chemistry. ACS medicinal chemistry letters 12 (2) (2021)
Dawit Wolday, Yazezew Kebede, Dorsisa Legesse, Dawd S Siraj, Joseph A McBride, Mitchell J Kirsch, Robert Striker
Role of CD4/CD8 ratio on the incidence of tuberculosis in HIV-infected patients on antiretroviral therapy followed up for more than a decade. PloS one 15 (5) (2020)
Adam J Schaenzer, Nathan Wlodarchak, David H Drewry, William J Zuercher, Warren E Rose, Carla A Ferrer, John-Demian Sauer, Robert Striker
GW779439X and Its Pyrazolopyridazine Derivatives Inhibit the Serine/Threonine Kinase Stk1 and Act As Antibiotic Adjuvants against β-Lactam-Resistant Staphylococcus aureus. ACS infectious diseases 4 (10) (2018)
Nathan Wlodarchak, Nathan Teachout, Jeffrey Beczkiewicz, Rebecca Procknow, Adam J Schaenzer, Kenneth Satyshur, Martin Pavelka, William J Zuercher, David Drewry, John-Demian Sauer, Robert Striker
In Silico Screen and Structural Analysis Identifies Bacterial Kinase Inhibitors which Act with β-Lactams To Inhibit Mycobacterial Growth. Molecular pharmaceutics 15 (11) (2018)